肝胆相照论坛

标题: 一个导弹工癌的研究 [打印本页]

作者: liver411    时间: 2010-7-1 18:26     标题: 一个导弹工癌的研究



这类东西往往到动物实验为止效果都不错,用到人身上就完了。
=======================================================
Trojan Horse For B-Cell Lymphoma

Sugar Chemistry: Chemical synthesis yields agents that target cancer cells

Stu Borman

By using chemical synthesis to add sugars to the surface of Trojan horse-like liposomes with a payload of anticancer agent, researchers have killed human B-cell lymphoma cells in blood and in live mice. This type of approach could lead to new therapeutics for B-cell lymphomas and other conditions.

B-cell lymphomas, cancers of immune-system B cells, are currently treated with doxorubicin and other chemotherapy agents or with monoclonal antibodies such as rituximab. These treatments have some moderate to severe side effects, and many patients still die from these cancers each year, so scientists continue to seek new medications.

Now, chemical glycobiologist James C. Paulson of Scripps Research Institute and coworkers have come up with a novel way to attack B-cell lymphomas (Blood 2010, 115, 4778). They synthesized a sialic acid-based glycan that serves as a ligand for CD22, a receptor found on the surface of B cells. They pinned a lipid tail onto the glycan via a polyethylene glycol linker. When they added the conjugate to liposomes, the glycans arrayed on the liposome surface. They then loaded the liposome cavity with the anticancer agent doxorubicin.

The glycan-studded liposomes act like Trojan horses when they encounter B cells. The B cells’ CD22 receptors recognize and bind multivalently to the glycans, and the B cells then absorb the liposomes by endocytosis. Once inside the B cells, the liposomes deliver their doxorubicin cargo, killing the cells.

When the researchers administered a high dose of the liposomes to mice with human lymphoma, five of eight cancerous mice survived, whereas all of the mice in a control group died. Afterward, no tumor cells could be detected in the bone marrow of any of the treated mice. The treatment also destroyed B cells in blood samples from human patients with three types of B-cell lymphoma.

“This is a great example of how chemical synthesis can allow you to achieve a level of specificity that wouldn’t be accessible with natural glycans,” comments Laura L. Kiessling of the University of Wisconsin, Madison, a specialist in protein-glycan interactions.

The approach currently kills CD22-bearing macrophages as well as B cells, so Paulson and coworkers hope to refine it to further improve its selectivity. “But that doesn’t detract from their having demonstrated that this kind of strategy can work,” Kiessling says.

“We are very interested in moving this technology forward to see if it would be applicable to treatment of humans and to investigate other applications for this kind of targeting,” Paulson says.
作者: 烟酒小子    时间: 2010-7-2 16:05

哎呀,实在看不懂什么,看人家没人回帖,我就回一下,也不知道说什么,不过26个字母认识
作者: freehuang    时间: 2010-8-8 19:38

就是说科学家在老鼠身上做了一个实验:把人类血液中的B淋巴癌细胞让它生活在老鼠的体内,然后用化学合成的方法把一种糖类负载到一种类似特洛伊木马的脂质体上制得抗癌药物,然后用这种药物去杀死老鼠体内的癌细胞,在老鼠体内杀死情况还不错,但是要真正用到人身体上,正如楼主所说有点困难,尽管科学家比较感兴趣,但是还没有结果!
作者: freehuang    时间: 2010-8-8 19:38

有待进一步研究




欢迎光临 肝胆相照论坛 (http://hbvhbv.info/forum/) Powered by Discuz! X1.5